Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.

31 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17

Sleep apnea clinical trials, in English

Obstructive sleep apnea trials may require a recent sleep study (AHI), CPAP intolerance, or a BMI range for medicine studies. Central sleep apnea is a different condition. We do not interpret your sleep study. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.

How to read this list

Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.

Phases in this snapshot: Not a traditional drug phase (24) · Phase 3 (3) · Phase 4 (2) · Phase 1 / Phase 2 (1) · Phase 2 (1)

Cities that appear on these records

  • Miami, Florida · 4
  • São Paulo, Brazil · 4
  • Cullman, Alabama · 3
  • Maplewood, Minnesota · 3
  • Cincinnati, Ohio · 3
  • Seoul, South Korea · 3
  • Madrid, Spain · 3
  • Beijing, China · 2

Browse by US state · city hubs

RecruitingNot a traditional drug phaseBethesda, Maryland
Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea

Background: Obstructive sleep apnea (OSA) occurs when the blockage of the airway causes a person to stop breathing involuntarily for 10 seconds or more throughout the night during sleep. Pediatric OSA can be especially concerning and can have long-term effects.

NCT05052216 · Official ClinicalTrials.gov record · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

RecruitingNot a traditional drug phaseSan Diego, California
Not a traditional drug phase: Positive Airway Pressure Device for Post Traumatic Stress Disorder

Substance use disorder (SUD) and posttraumatic stress disorder (PTSD) frequently co-occur and having both disorders is associated with greater psychological and functional impairment than having either disorder alone. This is especially true in residential settings where both disorders are more severe than outpatient settings.

NCT05156112 · Official ClinicalTrials.gov record · VA Office of Research and Development

RecruitingNot a traditional drug phaseBeijing
Not a traditional drug phase: Level III portable sleep study for Sleep Apnea

The investigators propose a prospective, watch-and-measure (no experimental treatment required) study to determine the impact of OSA and associated physiological parameters on clinical outcomes in patients with pulmonary hypertension. The prevalence, phenotypes, and predictors of OSA in the setting of pulmonary hypertension will also be investigated.

NCT05595200 · Official ClinicalTrials.gov record · Chinese Pulmonary Vascular Disease Research Group

RecruitingNot a traditional drug phaseTucson, Arizona
Not a traditional drug phase: Positive airway pressure for Obstructive Sleep Apnea

The Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL) study is a 5-year, multicenter randomly assigned open-label trial that will screen 400 cognitively normal older adults recruited from well-established sleep clinics at 4 academic medical centers, with newly diagnosed moderate-severe OSA. An expected 200 OSA patients will be then randomly assigned to one of two groups: i) a 3-month OSA treatment by any combination of PAP, OAT, and positional therapy that results in an "effective" AHI4%\< 10/hour and AHI3A\<20/hour (see below); ii) a waitlist control group to receive treatment at the conclusion of the 3-month intervention period.

NCT05988385 · Official ClinicalTrials.gov record · California Pacific Medical Center Research Institute

RecruitingPhase 4Columbia, Missouri
Phase 4: testing GLP-1 receptor agonist for Morbid Obesity

Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

NCT06132477 · Official ClinicalTrials.gov record · University of Missouri-Columbia

RecruitingNot a traditional drug phaseTainan, Taiwan
Not a traditional drug phase: Brief Behavioral Therapy for Insomnia (BBTi) for Comorbid Insomnia and Sleep Apnea

This study investigates the how well it works of a wearable voice-guided Brief Behavioral Therapy for Insomnia (BBTi) combined with a smart eye-mask device for individuals with Comorbid Insomnia and Sleep Apnea (COMISA). The four-year study comprises three phases: (1) exploration of cognitive-emotion regulation-arousal system mechanisms in COMISA and pilot BBTi intervention testing, (2) development and usability testing of an integrated smart eye-mask with BBTi voice-guided modules, and (3) a multi-center randomly assigned controlled trial (RCT) evaluating the combined BBTi plus smart eye-mask intervention versus BBTi alone, smart eye-mask alone, and standard sleep hygiene education in 160 COMISA participants.

NCT07521319 · Official ClinicalTrials.gov record · National Sun Yat-sen University

RecruitingPhase 2Chula Vista, California
Phase 2: testing IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide for Obstructive Sleep Apnea (OSA)

The goal of this randomly assigned, neither you nor the study doctors know who gets the real treatment, multi-dose crossover clinical trial is to determine the safety and how well it works of IHL-42X in subjects with obstructive sleep apnea. The primary endpoint is: Change in AHI4 at the end of each treatment period compared to baseline (each treatment period is 28 days).

NCT07635563 · Official ClinicalTrials.gov record · Incannex Healthcare Ltd

RecruitingPhase 4Tucson, Arizona
Phase 4: testing Atomoxetine-oxybutynin for Obstructive Sleep Apnea (OSA)

Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible you would be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions.

NCT07679282 · Official ClinicalTrials.gov record · Sairam Parthasarathy

RecruitingNot a traditional drug phaseHenderson, Nevada
Not a traditional drug phase: The study will assess the feasibility of incorporating the PLATO questionnaire into a dental sleep practice. The PLATO questionnaire was developed as a patient reported outcome measure for Obstructive Sleep Apnea (OSA)

Prospective, real-world watch-and-measure (no experimental treatment required) study in a dental sleep practice to assess the feasibility of incorporating the PLATO into a dental sleep practice and applicability for patients who are undergoing oral appliance therapy for the treatment of obstructive sleep apnea(OSA). The PLATO questionnaire was recently developed by the American Academy of Sleep Medicine specifically for use in patients with obstructive sleep apnea.

NCT07789834 · Official ClinicalTrials.gov record · Nevada Dental Sleep

RecruitingPhase 3Cullman, Alabama
Phase 3: testing Berobenatide for Apnea

This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \[OSA\]) and overweight or obesity who use a breathing machine (positive airway pressure \[PAP\] machine).

NCT07823608 · Official ClinicalTrials.gov record · Pfizer

RecruitingNot a traditional drug phaseLiège
Not a traditional drug phase: Cross-sectional assessment for Obstructive Sleep Disordered Breathing

The tongue plays a key role in maintaining upper airway patency during sleep, mainly through the genioglossus, the principal pharyngeal dilator muscle. Its dysfunction may be linked to the development of obstructive sleep-disordered breathing (oSDB), a condition affecting more than one in ten children and associated with cardiovascular and cognitive consequences.

NCT07861230 · Official ClinicalTrials.gov record · Université Catholique de Louvain

RecruitingNot a traditional drug phaseKaohsiung City
Not a traditional drug phase: Upper airway surgery for OSA for OSA - Obstructive Sleep Apnea

Dysphagia is a commonly reported complaint among patients with obstructive sleep apnea (OSA), particularly those who have undergone upper-airway (oropharyngeal) surgery. However, how surgical treatment for OSA affects swallowing function and oral function (oral frailty) remains unclear.

NCT07880067 · Official ClinicalTrials.gov record · National Sun Yat-sen University

RecruitingPhase 3Cullman, Alabama
Phase 3: testing Berobenatide for Apnea

This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive sleep apnea \[OSA\]) and overweight or obesity who are not using a breathing machine (positive airway pressure \[PAP\] machine).

NCT07881757 · Official ClinicalTrials.gov record · Pfizer

RecruitingNot a traditional drug phaseIstanbul, Göztepe
Not a traditional drug phase: Physical Activity Education for Obstructive Sleep Apnea

Although exercise and physical activity have shown beneficial effects in individuals with obstructive sleep apnea (OSA), evidence regarding the effects of daily physical activity habits on sleep quality and respiratory parameters remains limited. This study aims to investigate these associations in individuals with OSA.

NCT07889154 · Official ClinicalTrials.gov record · Medipol University

RecruitingNot a traditional drug phaseAl Mansurah, Dakahlia Governorate
Not a traditional drug phase: Transcutaneous Electrical Stimulation for Obstructive Sleep Apnea

* The aim of this study is to assess the impact of transcutaneous electrical stimulation on polysomnographic findings in obstructive sleep apnea patients. * The hypothesis of the present study is that nocturnal delivery of transcutaneous electrical stimulation of the pharyngeal dilators, in particular the genioglossus, may help in treating the functional loss of the neuromuscular tone with sleep onset to keep the Upper airway patent during sleep which would reduce the severity of OSA as measured by the apnea-hypopnea-index (AHI), so representing an alternative and better-tolerated approach compared to usual care with CPAP.

NCT07891702 · Official ClinicalTrials.gov record · Mansoura University

RecruitingNot a traditional drug phaseBeijing, Beijing Municipality
Development and Clinical Validation of Artificial Intelligence Algorithms for Sleep Staging and Obstructive…

In recent years, wearable and contactless devices, including smart rings, smart bands/watches, and smart mattresses, have developed rapidly and can continuously collect multidimensional data such as heart rate, oxygen saturation, respiration, body movement, snoring, body temperature, and environmental parameters. Nevertheless, most current consumer-grade or wellness-oriented devices have not been trained and validated using large polysomnography (PSG)-synchronized reference datasets.

NCT07908160 · Official ClinicalTrials.gov record · Peking University First Hospital

RecruitingNot a traditional drug phaseKaohsiung City
Not a traditional drug phase: Submental transcutaneous neuromuscular electrical stimulation (RS-18) for Obstructive Sleep Apnea

This single-arm pilot study evaluates the feasibility of nightly wearable monitoring with a ring-type sleep monitor during a 4-week home-based program of submental transcutaneous neuromuscular electrical stimulation in adults with obstructive sleep apnea, and describes changes in the ring-derived apnea-hypopnea index, sleep continuity, STOP-Bang score and upper-airway anatomy on CT before and after training.

NCT07921329 · Official ClinicalTrials.gov record · E-DA Hospital

RecruitingNot a traditional drug phaseNew Taipei City, New Taipei City
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Balli…

Obstructive sleep apnea (OSA) is a common sleep disorder associated with cardiovascular, metabolic, and neurocognitive complications. The standard diagnostic test for OSA is in-laboratory polysomnography (PSG), which can be costly, labor-intensive, and inconvenient for repeated or large-scale screening.

NCT07923825 · Official ClinicalTrials.gov record · Fu Jen Catholic University

FAQ: Sleep apnea trials

How do I find recruiting Sleep apnea clinical trials?

This hub lists 31 recruiting Sleep apnea studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “obstructive sleep apnea” at https://clinicaltrials.gov/search?cond=obstructive%20sleep%20apnea.

What does a Sleep apnea trial page on PlainTrials include?

A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.

Where are Sleep apnea studies located in this snapshot?

Sites that appear on these records include Miami, Florida; São Paulo, Brazil; Cullman, Alabama; Maplewood, Minnesota; Cincinnati, Ohio. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.

Can PlainTrials tell me if I qualify for a Sleep apnea study?

No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.

Related heart and lung hubs